Effect of urologists and medical oncologists on treatment of elderly men with stage IV prostate cancer

Urology

Volumn 77, Issue 5, 2011, Pages 1088-1095

  Onukwugha, Eberechukwu ^a,b,c   Mullins, C Daniel ^a,b,c   Doren Hsu, Van ^a,b,c   Seal, Brian ^a,b,c   Hussain, Arif ^a,b,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b SANOFI   (France)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; FLUOROURACIL; GOSERELIN; LEUPRORELIN; MITOXANTRONE; TAXANE DERIVATIVE; TRIPTORELIN;

ADVANCED CANCER; AFRICAN AMERICAN; AGED; AMBULATORY CARE; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER THERAPY; HISPANIC; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MEDICARE; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; HUMANS; INTERDISCIPLINARY COMMUNICATION; MALE; MEDICAL ONCOLOGY; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; UROLOGY;

EID: 79955634462     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.11.059     Document Type: Article

References (27)

1. Dogliotti L. Advanced prostate cancer: at last a role for medical oncologists. Eur Urol. 2007;51:4-5. (Pubitemid 44821533)
2. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520. (Pubitemid 39315318)
3. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512. (Pubitemid 39315317)
4. U.S. Food and Drug Administration. Cabazitaxel. Available at: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm216214.htm. Accessed July 22, 2010.
5. Fitzpatrick JM. A multidisciplinary team approach for the optimal clinical management of metastatic hormone-refractory prostate cancer-case study. Eur Urol Suppl. 2006;5:830-833.
6. Fitzpatrick JM, Anderson J, Sternberg CN, et al. Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach. Crit Rev Oncol/Hematol. 2008;68(suppl 1):S9-S22.
7. Townsley CA, Naidoo K, Pond GR, et al. Are older cancer patients being referred to oncologists? A mail questionnaire of Ontario primary care practitioners to evaluate their referral patterns. J Clin Oncol. 2003;21:4627-4635.
8. Earle CC, Neumann PJ, Gelber RD, et al. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol. 2002;20:1786-1792. (Pubitemid 34273267)
9. Steyerberg EW, Neville B, Weeks JC, et al. Referral patterns, treatment choices, and outcomes in locoregional esophageal cancer: a population-based analysis of elderly patients. J Clin Oncol. 2007;25:2389-2396. (Pubitemid 46999209)
10. Thwin SS, Fink AK, Lash TL, et al. Predictors and outcomes of surgeons' referral of older breast cancer patients to medical oncologists. Cancer. 2005;104:936-942. (Pubitemid 41170220)
11. Wang J, Kuo YF, Freeman J, et al. Increasing access to medical oncology consultation in older patients with stage II-IIIA non-small-cell lung cancer. Med Oncol. 2008;25:125-132.
12. American Medical Association. AMA Physician Masterfile 2009. Available at: http://www.ama-assn.org/ama/pub/about-ama/physician-data-resources/ physician-masterfile.shtml. Accessed June 15, 2009.
13. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
14. Parsons LS. Reducing bias in a propensity score-matched sample using greedy matching techniques. Presented at the 26th Annual SAS Users' Group International Conference, Long Beach, CA, 2002.
15. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44: 1049-1060. (Pubitemid 19026037)
16. Crawford ED. The role of the urologist in treating patients with hormone-refractory prostate cancer. Rev Urol. 2003;5(suppl 2):S48-S52.
17. Luo R, Giordano SH, Freeman JL, et al. Referral to medical oncology: a crucial step in the treatment of older patients with stage III colon cancer. Oncologist. 2006;11:1025-1033. (Pubitemid 44564812)
18. Wang J, Kuo YF, Freeman J, et al. Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung cancer. Cancer. 2008;112:382-390.
19. Baldwin LM, Taplin SH, Friedman H, et al. Access to multidisciplinary cancer care: is it linked to the use of breast-conserving surgery with radiation for early-stage breast carcinoma? Cancer. 2004;100:701-709. (Pubitemid 38176846)
20. Keating NL, Landrum MB, Ayanian JZ, et al. Consultation with a medical oncologist before surgery and type of surgery among elderly women with early-stage breast cancer. J Clin Oncol. 2003;21:4532-4539. (Pubitemid 46594023)
21. Calabro F, Sternberg CN. Current indications for chemotherapy in prostate cancer patients. Eur Urol. 2007;51:17-26. (Pubitemid 44821528)
22. Keating NL, O'Malley AJ, McNaughton-Collins M, et al. Use of androgen deprivation therapy for metastatic prostate cancer in older men. BJU Int. 2008;101:1077-1083. (Pubitemid 351502653)
23. Lu-Yao G, Moore DF, Oleynick JU, et al. Population based study of hormonal therapy and survival in men with metastatic prostate cancer. J Urol. 2007;177:535-539. (Pubitemid 46054022)
24. Zeliadt SB, Ramsey SD, Penson DF, et al. Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer. 2006;106:1865-1874. (Pubitemid 43673200)
25. Longford NT, Nelder JA. Statistics versus statistical science in the regulatory process. Stat Med. 1999;18:2311-2320. (Pubitemid 29423497)
26. Giordano SH, Kuo YF, Duan Z, et al. Limits of observational data in determining outcomes from cancer therapy. Cancer. 2008;112: 2456-2466.
27. Yu JB, Gross CP, Wilson LD, et al. NCI SEER public-use data: applications and limitations in oncology research. Oncology (Williston Park). 2009;23:288-295.